Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Income towards Parent Company (2016 - 2025)

Moleculin Biotech's Income towards Parent Company history spans 10 years, with the latest figure at -$7.5 million for Q4 2025.

  • Quarterly results put Income towards Parent Company at -$7.5 million for Q4 2025, down 14.07% from a year ago — trailing twelve months through Dec 2025 was -$25.0 million (up 4.19% YoY), and the annual figure for FY2025 was -$25.0 million, up 4.19%.
  • Income towards Parent Company for Q4 2025 was -$7.5 million at Moleculin Biotech, down from -$5.9 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of -$5.5 million in Q2 2021 to a low of -$41.0 million in Q4 2023.
  • The 5-year median for Income towards Parent Company is -$6.5 million (2024), against an average of -$10.5 million.
  • The sharpest move saw Income towards Parent Company plummeted 810.5% in 2021, then skyrocketed 83.9% in 2024.
  • Year by year, Income towards Parent Company stood at -$24.0 million in 2021, then crashed by 35.75% to -$32.6 million in 2022, then decreased by 25.59% to -$41.0 million in 2023, then skyrocketed by 83.9% to -$6.6 million in 2024, then fell by 14.07% to -$7.5 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at -$7.5 million, -$5.9 million, and -$5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.